QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CRVS

QT64Corvus Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
11.91
-0.09-0.75%
OverviewShort InterestFilings
CRVSQT64Corvus Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
11.91-0.75%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own37.56%
Shs Outstand84.09M
Perf Week2.67%
Market Cap1.01BForward P/E-EPS next Y-0.85Insider Trans0.53%Shs Float-Perf Month3.57%
Enterprise Value969.82MPEG0.10EPS next Q-0.17Inst Own-Short Float-Perf Quarter-15.47%
Income-41271568.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y50.00%
Sales-P/B4.49EPS next Y-25.46%ROA-17.44%Short Interest-Perf YTD54.68%
Book/sh0.73P/C-EPS next 5Y-ROE-38.92%52W High26.95 -55.81%Perf Year202.28%
Cash/sh0.68P/FCF-EPS past 3/5Y-ROIC-19.84%52W Low3.55 235.49%Perf 3Y-
Dividend Est.-EV/EBITDA-22.94Sales past 3/5Y-Gross Margin0.00%Volatility4.21% 4.33%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM49.02%Oper. Margin0.00%ATR (14)0.81Perf 10Y-
Dividend Ex-Date-Quick Ratio19.81Sales Y/Y TTM-Profit Margin0.00%RSI (14)43.51Recom2.00
Dividend Gr. 3/5Y-Current Ratio19.81EPS Q/Q-15.38%SMA20-0.39%Beta-0.47Target Price33.17
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-14.10%Rel Volume1.29Prev Close12.00
Employees31LT Debt/Eq0.02EarningsAug 06SMA2000.57%Avg Volume1.54MPrice11.91
IPO DateMar 23, 2016Option/ShortYes / YesEPS/Sales Surpr.-7.14% -Net Debt/EBITDA0.93Volume1,976,070Change-0.75%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-17-26InitiatedGoldman SachsBuy$40
Jan-29-26ReiteratedMizuho Securities$20 → $30
Jan-22-26ReiteratedJefferiesBuy$13 → $42
Jan-21-26ReiteratedOppenheimerOutperform$7.00 → $32
Jan-20-26ReiteratedMizuho Securities$13 → $20
Jan-20-26ReiteratedH.C. WainwrightBuy$11 → $27
Oct-29-25ReiteratedMizuho Securities$11 → $13
Oct-13-25InitiatedBarclaysOverweight$16
May-20-25ReiteratedMizuho Securities$12 → $11
Nov-13-24ReiteratedJefferiesBuy$13
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit000
Selling, General and Administrative Excl. Other987
Research and Development341917
Other Operating Expense01-1
Operating Income-43-28-23
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-28354
Net Income Before Taxes-15-62-27
Income Taxes
000
Consolidated Net Income-15-62-27
Net Income From Continuing Operations-15-62-27
Net Income-15-62-27
EPS (Recurring)-0.19-1.02-0.56
EPS (Basic, Before Extraordinaries)-0.19-1.02-0.56
EPS (Diluted)-0.53-1.02-0.56
EBITDA-15-62-27
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding796148
Market Capitalization608——
Operating Lease Expense
———
Insider Trading Volume
$12.84$10.97$9.10$7.23$5.36● Close Price0.00M2.45M4.89M7.34M9.78MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Moore David ScottDirectorJun 11 '26Buy11.5321,700250,23621,700Jun 15 12:00 AM
MILLER RICHARD A MDPresident and CEOMay 18 '26Buy12.046,93283,4531,195,035May 20 12:00 AM
Thompson Peter A.director, 10 percent owner:Jan 28 '26Option Exercise5.33420,0002,238,748210,000Jan 30 12:00 AM
ORBIMED ADVISORS LLCdirector, 10 percent owner:Jun 27 '25Option Exercise3.502,795,3689,783,7888,341,338Jul 01 12:00 AM
ORBIMED ADVISORS LLCdirector, 10 percent owner:Jun 27 '25Sale4.161,176,3324,891,8947,165,006Jul 01 12:00 AM
Thompson Peter A.director, 10 percent owner:Jun 27 '25Option Exercise3.502,795,3689,783,7888,341,338Jul 01 12:00 AM
Thompson Peter A.director, 10 percent owner:Jun 27 '25Sale4.161,176,3324,891,8947,165,006Jul 01 12:00 AM
Jones William BentonSee RemarksJun 04 '25Option Exercise3.5038,714135,500173,130Jun 06 12:00 AM
MILLER RICHARD A MDPresident and CEOMay 07 '25Option Exercise3.501,118,1463,913,5121,136,707May 09 12:00 AM
Thompson Peter A.director, 10 percent owner:May 06 '24Buy1.722,841,7694,892,0381,444,085May 08 12:00 AM
ORBIMED ADVISORS LLCdirector, 10 percent owner:May 06 '24Buy1.722,841,7694,892,0381,444,085May 08 12:00 AM
Jones William BentonSee RemarksMay 06 '24Buy2.6039,357102,374153,773May 07 12:00 AM
MILLER RICHARD A MDPresident and CEOMay 06 '24Buy2.601,136,7072,956,756577,634May 07 12:00 AM
Grais LindaDirectorMay 15 '23Buy2.4510,00024,50010,000May 16 12:00 AM
Jones William BentonSee RemarksDec 20 '22Buy0.7920,00015,800133,773Dec 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR